[Fundamental and clinical studies of sulbactam/cefoperazone in the pediatric field]. 1984

T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga

To 6 cases of children in 2 groups of 3 each, newly developed sulbactam/cefoperazone (SBT/CPZ) was given at 20 and 40 mg/kg by intravenous bolus injection, respectively, and the serum and urinary concentrations and recoveries of SBT and CPZ were determined. To 1 case of purulent meningitis, this drug was given at 40 mg/kg by intravenous bolus injection, and the cerebrospinal fluid and serum concentrations of SBT and CPZ were determined. Susceptibility tests to SBT/CPZ and CPZ of total 289 strains were conducted; Gram-positive cocci tested consisted of 26 S. aureus strains, 20 S. pyogenes strains and 21 S. pneumoniae strains, and Gram-negative bacilli consisted of 24 H. influenzae strains, 22 E. coli strains, 26 K. pneumoniae strains, 24 E. cloacae strains, 21 E. aerogenes strains, 19 Citrobacter sp. strains, 20 S. marcescens strains, 23 P. mirabilis strains, 23 indole-positive Proteus sp. strains and 20 P. aeruginosa strains. SBT/CPZ was given to total 43 cases at a mean daily dosage of 80.4 mg/kg, in 3 or 4 divided doses (6 cases in 3 and 37 cases in 4), 1 case receiving the drug by drip infusion over 30 minutes (in 3 divided doses) and all the other 42 cases by intravenous bolus injection, for 7 days on an average. They consisted of 2 cases of tonsillitis, 1 case of otitis media, 1 case of otitis media associated with mastoiditis, 30 cases of pneumonia, 1 case of suspected septicemia, 1 case of purulent meningitis, 5 cases of urinary tract infection, 1 case of purulent lymphadenitis and 1 case of submaxillaritis. And the clinical and bacteriological effects were evaluated. Also, side reactions and laboratory examinations for abnormal values due to administration of this drug were made on 47 cases including 4 drop-outs. The following results were obtained: After administration of this drug to 2 groups of 3 children each at 20 and 40 mg/kg by intravenous bolus injection, mean serum concentrations of both SBT and CPZ reached the peaks in 5 minutes; SBT levels were 60.9 and 124.7 micrograms/ml for the 2 groups and CPZ levels were 105.0 and 214.1 micrograms/ml, respectively. In either group, CPZ levels were 1.7 times as high as SBT levels, and there was observed a dose-response in both. In the 20 mg/kg group, mean half-lives of SBT and CPZ were 0.96 and 1.24 hours, respectively, and in the 40 mg/kg group, they were 1.01 and 1.32 hours, CPZ values tending to be longer.(ABSTRACT TRUNCATED AT 400 WORDS)

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D010397 Penicillanic Acid A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed) Acid, Penicillanic
D002438 Cefoperazone Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections. Cefobid,Cefoperazon,Cefoperazone Sodium,Cefoperazone Sodium Salt,Céfobis,T-1551,T1551,Salt, Cefoperazone Sodium,Sodium Salt, Cefoperazone,Sodium, Cefoperazone,T 1551
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females

Related Publications

T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
October 1984, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
October 1984, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
October 1984, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
November 1984, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
October 1984, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
October 1984, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
October 1984, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
November 1984, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
October 1984, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
November 1984, The Japanese journal of antibiotics,
Copied contents to your clipboard!